Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Novavax (Nasdaq: NVAX) will report fourth quarter and full year 2025 financial results and operational highlights on February 26, 2026 at 8:30 a.m. ET.
Investors may join the live conference call by registering for an automated call back or by dialing in; a replay and webcast will be available after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NVAX showed a modest 0.46% gain pre-announcement. Among close biotech peers, ABCL appeared in momentum scans, moving 1.2799999676644802% up without news, while other peers showed mixed single-day moves. Overall action appears more stock-specific than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | License agreement | Positive | +2.4% | Pfizer license for Matrix‑M with upfront and milestone payments. |
| Jan 07 | Conference participation | Neutral | +2.4% | Participation in 44th J.P. Morgan Healthcare Conference with webcast. |
| Nov 12 | Conference participation | Neutral | -3.2% | Jefferies London Healthcare Conference fireside chat announcement. |
| Nov 06 | Earnings release | Negative | -1.3% | Q3 2025 results with $70M revenue and $202M net loss. |
| Nov 04 | Milestone payment | Positive | -5.1% | Completion of U.S. marketing authorization transfer to Sanofi with $25M milestone. |
Recent company news has produced mixed reactions: positive strategic deals and conference updates sometimes aligned with modest gains, while milestone and earnings headlines have at times coincided with declines.
Over the last several months, Novavax has combined partnership, regulatory, and earnings developments. A January 20, 2026 non‑exclusive Matrix‑M license with Pfizer brought a $30M upfront payment and up to $500M in milestones, with shares rising about 2–3%. Participation in major conferences like J.P. Morgan and Jefferies produced modest but mixed price reactions. Earlier, Q3 2025 results showed $70M revenue and a $202M net loss, while Sanofi‑related milestones and U.S. marketing authorization transfer headlines coincided with short‑term weakness. Today’s earnings-date announcement fits into this ongoing cadence of financial and strategic updates.
Market Pulse Summary
This announcement sets the timing for Novavax’s fourth quarter and full year 2025 results on February 26, 2026 at 8:30 a.m. ET, with replay access extending into March. In recent months the company highlighted a major Matrix‑M license with Pfizer, Sanofi‑related milestones, and Q3 2025 results showing both revenue and sizable losses. Investors will likely focus on updated revenue composition, cash position, and partnership contributions once the detailed 2025 figures and operational commentary are released.
AI-generated analysis. Not financial advice.
Conference call details: | |
Date: | February 26, 2026 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 ( |
(+1) (646) 357-8766 (International) | |
Webcast: | |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, February 26, 2026, until 11:59 p.m. ET, March 5, 2026 |
Dial-in number: | (800) 770-2030 ( |
(+1) (609) 800-9909 (International) | |
Passcode: | 9610065# |
Webcast: | ir.novavax.com/events, until March 25, 2026 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-302692051.html
SOURCE Novavax, Inc.
FAQ
When will Novavax (NVAX) report fourth quarter and full year 2025 results?
How can investors join the Novavax (NVAX) earnings conference call on February 26, 2026?
What are the dial‑in and webcast details for Novavax (NVAX) on February 26, 2026?
When and how long will the Novavax (NVAX) replay be available after the February 26, 2026 call?
Is a webcast provided for Novavax (NVAX) fourth quarter and full year 2025 results?
What will Novavax (NVAX) cover during the February 26, 2026 presentation?
